| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
MDGL
Madrigal Pharmaceuticals
|
May 07, 2026 | BUY |
Strong Buy
-4.7% avg upside
31 analysts
|
$649.00
31.35% Upside
|
-10.1% |
|
VTVT
vTv Therapeutics
|
Mar 12, 2026 | BUY |
Strong Buy
-4.1% avg upside
12 analysts
|
$44.00
30.73% Upside
|
+0.1% |
|
ALT
Altimmune
|
Aug 22, 2025 | BUY |
Strong Buy
+935.0% avg upside
19 analysts
|
$25.00
824.26% Upside
|
-18.1% |
|
SKYE
Skye Bioscience
|
Aug 15, 2025 | BUY |
Strong Buy
+1327.3% avg upside
9 analysts
|
$10.00
1268.80% Upside
|
-76.9% |
|
HALO
Halozyme
|
May 15, 2025 | BUY |
Strong Buy
-13.1% avg upside
20 analysts
|
$55.00
18.45% Downside
|
+37.1% |
|
ATRA
Atara Biotherapeutics
|
Nov 09, 2023 | HOLD |
Buy
+86.0% avg upside
18 analysts
|
— | +88.5% |
|
CLYM
Climb Bio
|
Sep 08, 2021 | BUY |
Strong Buy
+59.3% avg upside
18 analysts
|
— | -87.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.